Category
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Today's News
More News
Traumatic Ulcerative Granuloma With Stromal Eosinophilia: A Case Report

Traumatic Ulcerative Granuloma With Stromal Eosinophilia: A Case Report

Written by: Drs. Ronald S. Brown, James T. Castle, Gail Cherry-Peppers, and Crystal McIntoshINTRODUCTIONTraumatic ulcerative granuloma with stromal eosinophilia (TUGSE) is a relatively rare, ben

Traumatic Ulcerative Granuloma With Stromal Eosinophilia: A Case Report

Written by: Drs. Ronald S. Brown, James T. Castle, Gail Cherry-Peppers, and Crystal McIntoshINTRODUCTIONTraumatic ulcerative granuloma with stromal eosinophilia (TUGSE) is a relatively rare, ben
Vaping threatens oral health as much as smoking

Vaping threatens oral health as much as smoking

Dental News3 weeks agoFor years, it has been known that smoking can contribute to serious damage on gum and oral health, with smokers having more gum diseases, more tooth loss, and increased levels of

Vaping threatens oral health as much as smoking

Dental News3 weeks agoFor years, it has been known that smoking can contribute to serious damage on gum and oral health, with smokers having more gum diseases, more tooth loss, and increased levels of
Worried about your child's teeth? Focus on these three things

Worried about your child's teeth? Focus on these three things

by Mihiri Silva, Elodie O'Connor, Rachelle Welti and Sharon Goldfeld,The ConversationCredit: CC0 Public DomainOne in three Australian childrenhave tooth decay by the time they start sc

Worried about your child's teeth? Focus on these three things

by Mihiri Silva, Elodie O'Connor, Rachelle Welti and Sharon Goldfeld,The ConversationCredit: CC0 Public DomainOne in three Australian childrenhave tooth decay by the time they start sc
Large-scale study reveals new genetic details of diabetes

Large-scale study reveals new genetic details of diabetes

by Wynne Parry,Cornell UniversityGraphical Abstract. Credit:Cell Metabolism(2023). DOI: 10.1016/jNaNet.2023.09.013In experiments of unprecedented scale, investigators at Weill Cornel

Large-scale study reveals new genetic details of diabetes

by Wynne Parry,Cornell UniversityGraphical Abstract. Credit:Cell Metabolism(2023). DOI: 10.1016/jNaNet.2023.09.013In experiments of unprecedented scale, investigators at Weill Cornel
Belzutifan outperforms everolimus in advanced kidney cancer treatment

Belzutifan outperforms everolimus in advanced kidney cancer treatment

byDana-Farber Cancer InstituteCredit: CC0 Public DomainBelzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer,

Belzutifan outperforms everolimus in advanced kidney cancer treatment

byDana-Farber Cancer InstituteCredit: CC0 Public DomainBelzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer,
Tumor Profiling Studies Illuminate Nuances Across Malignancies

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21, 2022Megan HollaschMolecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods ar

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21, 2022Megan HollaschMolecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods ar
Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa
CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung
Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l

Adjuvant capecitabine after CRT improves survival in locally advanced nasopharynx

October 25, 2022Jason HarrisTreatment with adjuvant capecitabine following concurrent chemoradiotherapy resulted in superior failure-free survival compared with observation and CRT for patients with l
Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia

Camrelizumab Plus Nab-Paclitaxel Showcases Antitumor Activity in Platinum-Resistant Urothelial

September 30, 2022Ryan ScottThe combination of camrelizumab and nab-paclitaxel produced encouraging responses in patients with platinum-resistant, unresectable locally advanced or metastatic urothelia
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...